Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDDate | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
08/07/2023 | Q2 2023 | -$4.71 | -$3.00 | 1.71 | $5.90 M | |
05/09/2023 | Q1 2023 | -$0.23 | -$0.23 | 0 | $4.86 M | |
03/14/2023 | Q4 2022 | $0.38 | -$0.17 | -0.55 | $2.64 M | |
11/10/2022 | Q3 2022 | -$5.59 | -$0.28 | 5.31 | $4.25 M | |
08/04/2022 | Q2 2022 | -$5.98 | -$0.45 | 5.53 | $2.88 M | |
05/12/2022 | Q1 2022 | -$3.90 | -$5.57 | -1.67 | $3.17 M | |
03/14/2022 | Q4 2021 | -$5.98 | -$0.55 | 5.43 | $1.99 M | |
11/10/2021 | Q3 2021 | -$8.97 | -$8.17 | 0.8 | $1.95 M | |
08/10/2021 | Q2 2021 | -$7.54 | -$8.42 | -0.88 | $2.70 M | |
05/10/2021 | Q1 2021 | -$7.28 | -$7.83 | -0.55 | $2.96 M | |
03/18/2021 | Q4 2020 | $1.37 | -$1.15 | -2.52 | $3.76 M | |
09/29/2020 | Q3 2020 | -$5.96 | $4.20 M | |||
06/29/2020 | Q2 2020 | -$8.33 | $1.95 M | |||
03/30/2020 | Q1 2020 | -$7.87 | $3.47 M | |||
12/30/2019 | Q4 2019 | $0.00 | $3.10 M |
Sigilon Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 8th, 2023 based off last year's report dates.
In the previous quarter, Sigilon Therapeutics, Inc. (:SGTX) reported $-2.89 earnings per share (EPS) to beat the analysts' consensus estimate of $-4.71 by $1.82.
The conference call for Sigilon Therapeutics, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Sigilon Therapeutics, Inc.'s latest earnings report can be read online.
Sigilon Therapeutics, Inc. (:SGTX) has a recorded annual revenue of $12.94 M.
Sigilon Therapeutics, Inc. (:SGTX) has a recorded net income of $12.94 M. Sigilon Therapeutics, Inc. has generated $-1.34 earnings per share over the last four quarters.
Sigilon Therapeutics, Inc. (:SGTX) has a price-to-earnings ratio of -16.76 and price/earnings-to-growth ratio is -0.17.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED